| [1] |
LINARES L, SANCLEMENTE G, CERVERA C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients[J]. Transplant Proc, 2011, 43(6):2145-2148. DOI: 10.1016/j.transproceed.2011.05.007.
|
| [2] |
CANNON MJ, SCHMID DS, HYDE TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection[J]. Rev Med Virol, 2010, 20(4):202-213. DOI: 10.1002/rmv.655.
|
| [3] |
RAZONABLE R. Direct and indirect effects of cytomegalovirus: can we prevent them?[J]. Enferm Infecc Microbiol Clin, 2010, 28(1):1-5. DOI: 10.1016/j.eimc.2009.07.008.
|
| [4] |
WALKER RC, MARSHALL WF, STRICKLER JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder[J]. Clin Infect Dis, 1995, 20(5):1346-1353. doi: 10.1093/clinids/20.5.1346
|
| [5] |
GEORGE MJ, SNYDMAN DR, WERNER BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland[J]. Am J Med, 1997, 103(2):106-113. doi: 10.1016/S0002-9343(97)80021-6
|
| [6] |
HELANTERÄ I, LAUTENSCHLAGER I, KOSKINEN P. The risk of cytomegalovirus recurrence after kidney transplantation[J]. Transpl Int, 2011, 24(12):1170-1178. DOI: 10.1111/j.1432-2277.2011.01321.x.
|
| [7] |
HUMAR A, SNYDMAN D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 4): S78-S86. DOI: 10.1111/j.1600-6143.2009.02897.x.
|
| [8] |
RAZONABLE RR, HUMAR A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation[J]. Am J Transplant, 2013,13(Suppl 4):93-106. DOI: 10.1111/ajt.12103.
|
| [9] |
DORON S, RUTHAZER R, WERNER BG, et al.Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes[J]. Transplantation,2006, 81(5):697-703. doi: 10.1097/01.tp.0000180531.66518.9e
|
| [10] |
KOTTON CN, KUMAR D, CALIENDO AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[J]. Transplantation, 2018, 102(6):900-931. DOI: 10.1097/TP.0000000000002191.
|
| [11] |
GOLDFARB NS, AVERY RK, GOORMASTIC M, et al. Hypogammaglobulinemia in lung transplant recipients[J]. Transplantation, 2001, 71(2):242-246. doi: 10.1097/00007890-200101270-00013
|
| [12] |
ESHRAGHI H, HEKMAT R. Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients?[J]. Transplant Proc, 2015, 47(4):1136-1139. DOI: 10.1016/j.transproceed.2014.11.066.
|
| [13] |
KANTER J, PALLARDÓ L, GAVELA E, et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome[J]. Transplant Proc, 2009, 41(6):2156-2158. DOI: 10.1016/j.transproceed.2009.06.057.
|
| [14] |
FISHMAN JA, GROSSI PA. Donor-derived infection--the challenge for transplant safety[J]. Nat Rev Nephrol, 2014, 10(11):663-672. DOI: 10.1038/nrneph.2014.159.
|
| [15] |
RAZONABLE RR, PAYA CV, SMITH TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients[J]. J Clin Microbiol, 2002, 40(3):746-752. doi: 10.1128/JCM.40.3.746-752.2002
|
| [16] |
BEAM E, RAZONABLE RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment[J]. Curr Infect Dis Rep, 2012, 14(6):633-641. DOI: 10.1007/s11908-012-0292-2.
|
| [17] |
STRIPPOLI GF, HODSON EM, JONES C, et al. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients[J]. Transplantation, 2006, 81(2):139-145. doi: 10.1097/01.tp.0000183970.71366.da
|
| [18] |
EID AJ, RAZONABLE RR. New developments in the management of cytomegalovirus infection after solid organ transplantation[J]. Drugs, 2010, 70(8):965-981. DOI: 10.2165/10898540-000000000-00000.
|
| [19] |
HIBBERD PL, TOLKOFF-RUBIN NE, CONTI D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. a randomized controlled trial[J]. Ann Intern Med, 1995, 123(1):18-26. doi: 10.7326/0003-4819-123-1-199507010-00002
|
| [20] |
JAMAL AJ, HUSAIN S, LI Y, et al. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients[J]. Transplantation, 2014, 97(5):569-575. DOI: 10.1097/01.tp.0000438197.38413.f2.
|
| [21] |
ASBERG A, HUMAR A, ROLLAG H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients[J]. Am J Transplant, 2007, 7(9):2106-2113. doi: 10.1111/ajt.2007.7.issue-9
|
| [22] |
TORRE-CISNEROS J, AGUADO JM, CASTON JJ, et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations[J]. Transplant Rev (Orlando), 2016, 30(3):119-143. DOI: 10.1016/j.trre.2016.04.001.
|
| [23] |
BHORADE SM, LURAIN NS, JORDAN A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients[J]. J Heart Lung Transplant, 2002, 21(12):1274-1282. doi: 10.1016/S1053-2498(02)00463-1
|
| [24] |
LURAIN NS, CHOU S. Antiviral drug resistance of human cytomegalovirus[J]. Clin Microbiol Rev, 2010, 23(4):689-712. DOI: 10.1128/CMR.00009-10.
|
| [25] |
GREEN M, MICHAELS MG, KATZ BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients[J]. Am J Transplant, 2006, 6(8):1906-1912. doi: 10.1111/ajt.2006.6.issue-8
|
| [26] |
KELLY DA, BUCUVALAS JC, ALONSO EM, et al. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(8):798-825. DOI: 10.1002/lt.23697.
|
| [27] |
KIZILARSLANOGLU MC, AKSOY S, YILDIRIM NO, et al. Temozolomide-related infections: review of the literature[J]. J BUON, 2011, 16(3):547-550. http://cn.bing.com/academic/profile?id=ebafc8f55b31f53d7360e0ac4190dc29&encoded=0&v=paper_preview&mkt=zh-cn
|
Figures(3)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad:
